AB0092 ANTISYNTHETASE SYNDROME: CLINICAL PROFILE, SEROLOGIC AND TREATMENTS USED IN A COHORT OF PATIENTS FOLLOWED AT THE VIRGEN MACARENA HOSPITAL

Background: The antisynthetase syndrome (SAS) is characterized by the presence of antibodies, anti-JO1, PL7 y PL12 are most common; and classic triad myositis, arthritis, diffuse interstitial lung disease (ILD) 1 . Most patients present incomplete forms severity ILD determines prognosis 2 Objectives: to analyze epidemiological, clinical serological characteristics treatments used in a cohort with SAS. Methods: descriptive study review medical records. Data were collected from 15 SAS followed Rheumatology Pneumology consultations Virgen Macarena Hospital (Seville) last 10 years. analysis was carried out using R software. Results: included, 8 men 7 women. median age 56 years (33-77). Seven (47%) smoke. Four (27%) met classical triad. All them presented (53%) had arthritis / or myositis. Five (33%) mechanic’s hands six (40%) Raynaud. suffered dyspnea before diagnosis. diagnostic delay month (0-43). (7%) anti-PL7, (13%) anti-PL12 anti-Ro52. Radiological patterns detected HRCT were: 5 NINE, 4 (37%) NIU 6 others. initial treatment included mostly (66%) glucocorticoids (GC) one more cFAME. In maintenance, mycophenolate (47%), cyclosporine (33%), cyclophosphamide 3 cases (20%), azathioprine (20%) methotrexate (20%). required combination DMARDs needed biological therapy, Rituximab Tocilizumab. Changes mean value respiratory function tests (FVC1 DLCO1) during follow-up (FVC2 DLCO2) not relevant 81.5% [42-110], FVC2 81% [59-115]; DLCO1 83% [10-112], DLCO2 80.5% [47-108]). Nine (60%) remained clinically stable progressed radiologically. died progression. Conclusion: this study, diagnosis predominated. antibody anti-JO1. all cases, NINE being frequent pattern so multidisciplinary management necessary. GC FAMES combined, some therapy. References: [1]Irazoque F, et al. Epidemiology, etiology classification. Reumatol Clin. 2009;5:2-5. [2]Johnson C, Clinical pathologic differences based on type. Respir Med. 2014; 108(10):1542-8. Disclosure Interests: None declared